Cargando…

External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy

BACKGROUND: Shared decision making is nowadays acknowledged as an essential step when deciding on starting renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this regard. We intended to validate a recently published risk stratificatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeters, Patrick, Van Biesen, Wim, Veys, Nic, Lemahieu, Wim, De Moor, Bart, De Meester, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823864/
https://www.ncbi.nlm.nih.gov/pubmed/27055653
http://dx.doi.org/10.1186/s12882-016-0253-3
_version_ 1782425997411352576
author Peeters, Patrick
Van Biesen, Wim
Veys, Nic
Lemahieu, Wim
De Moor, Bart
De Meester, Johan
author_facet Peeters, Patrick
Van Biesen, Wim
Veys, Nic
Lemahieu, Wim
De Moor, Bart
De Meester, Johan
author_sort Peeters, Patrick
collection PubMed
description BACKGROUND: Shared decision making is nowadays acknowledged as an essential step when deciding on starting renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this regard. We intended to validate a recently published risk stratification model in a large cohort of incident patients starting renal replacement therapy in Flanders. METHODS: During 3 years (2001–2003), the data set collected for the Nederlandstalige Belgische Vereniging voor Nefrologie (NBVN) registry was expanded with parameters of comorbidity. For all incident patients, the abbreviated REIN score(aREIN), being the REIN score without the parameter “mobility”, was calculated, and prognostication of mortality at 3, 6 and 12 month after start of renal replacement therapy (RRT) was evaluated. RESULTS: Three thousand four hundred seventy-two patients started RRT in Flanders during the observation period (mean age 67.6 ± 14.3, 56.7 % men, 33.6 % diabetes). The mean aREIN score was 4.1 ± 2.8, and 56.8, 23.1, 12.6 and 7.4 % of patients had a score of ≤4, 5–6, 7–8 or ≥9 respectively. Mortality at 3, 6 and 12 months was 8.6, 14.1 and 19.6 % in the overall and 13.2, 21.5 and 31.9 % in the group with age >75 respectively. In RoC analysis, the aREIN score had an AUC of 0.74 for prediction of survival at 3, 6 and 12 months. There was an incremental increase in mortality with the aREIN score from 5.6 to 45.8 % mortality at 6 months for those with a score ≤4 or ≥9 respectively. CONCLUSION: The aREIN score is a useful tool to predict short term prognosis of patients starting renal replacement therapy as based on comorbidity and age, and delivers meaningful discrimination between low and high risk populations. As such, it can be a useful instrument to be incorporated in shared decision making on whether or not start of dialysis is worthwhile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-016-0253-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4823864
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48238642016-04-08 External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy Peeters, Patrick Van Biesen, Wim Veys, Nic Lemahieu, Wim De Moor, Bart De Meester, Johan BMC Nephrol Research Article BACKGROUND: Shared decision making is nowadays acknowledged as an essential step when deciding on starting renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this regard. We intended to validate a recently published risk stratification model in a large cohort of incident patients starting renal replacement therapy in Flanders. METHODS: During 3 years (2001–2003), the data set collected for the Nederlandstalige Belgische Vereniging voor Nefrologie (NBVN) registry was expanded with parameters of comorbidity. For all incident patients, the abbreviated REIN score(aREIN), being the REIN score without the parameter “mobility”, was calculated, and prognostication of mortality at 3, 6 and 12 month after start of renal replacement therapy (RRT) was evaluated. RESULTS: Three thousand four hundred seventy-two patients started RRT in Flanders during the observation period (mean age 67.6 ± 14.3, 56.7 % men, 33.6 % diabetes). The mean aREIN score was 4.1 ± 2.8, and 56.8, 23.1, 12.6 and 7.4 % of patients had a score of ≤4, 5–6, 7–8 or ≥9 respectively. Mortality at 3, 6 and 12 months was 8.6, 14.1 and 19.6 % in the overall and 13.2, 21.5 and 31.9 % in the group with age >75 respectively. In RoC analysis, the aREIN score had an AUC of 0.74 for prediction of survival at 3, 6 and 12 months. There was an incremental increase in mortality with the aREIN score from 5.6 to 45.8 % mortality at 6 months for those with a score ≤4 or ≥9 respectively. CONCLUSION: The aREIN score is a useful tool to predict short term prognosis of patients starting renal replacement therapy as based on comorbidity and age, and delivers meaningful discrimination between low and high risk populations. As such, it can be a useful instrument to be incorporated in shared decision making on whether or not start of dialysis is worthwhile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-016-0253-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-07 /pmc/articles/PMC4823864/ /pubmed/27055653 http://dx.doi.org/10.1186/s12882-016-0253-3 Text en © Peeters et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Peeters, Patrick
Van Biesen, Wim
Veys, Nic
Lemahieu, Wim
De Moor, Bart
De Meester, Johan
External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
title External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
title_full External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
title_fullStr External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
title_full_unstemmed External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
title_short External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
title_sort external validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823864/
https://www.ncbi.nlm.nih.gov/pubmed/27055653
http://dx.doi.org/10.1186/s12882-016-0253-3
work_keys_str_mv AT peeterspatrick externalvalidationofariskstratificationmodeltoassistshareddecisionmakingforpatientsstartingrenalreplacementtherapy
AT vanbiesenwim externalvalidationofariskstratificationmodeltoassistshareddecisionmakingforpatientsstartingrenalreplacementtherapy
AT veysnic externalvalidationofariskstratificationmodeltoassistshareddecisionmakingforpatientsstartingrenalreplacementtherapy
AT lemahieuwim externalvalidationofariskstratificationmodeltoassistshareddecisionmakingforpatientsstartingrenalreplacementtherapy
AT demoorbart externalvalidationofariskstratificationmodeltoassistshareddecisionmakingforpatientsstartingrenalreplacementtherapy
AT demeesterjohan externalvalidationofariskstratificationmodeltoassistshareddecisionmakingforpatientsstartingrenalreplacementtherapy